4 / 28
Page 46
Notes:
allied
academies
Cell Science, Stem Cell Research &
Pharmacological Regenerative Medicine
November 29-30, 2017 | Atlanta, USA
Annual Congress on
Adv cel sci tissue cul 2017 | Volume 1 Issue 2
Lipid-lowering and antioxidant effects of policosanol in diabetic patients: A pilot study
Julio C Fernández
1
, José Illnait
1
, Lilia Fernández
1
, Sarahí Mendoza
1
, Ambar Oyarzábal
1
, Sonia Jiménez
1
, Meilis Mesa
2
and
Ernesto López
2
1
National Centre for Scientific Research, Cuba
2
Medical Surgical Research Centre, Cuba
Introduction:
Coronary artery disease is the major
complication and leading cause of death among patients with
diabetes mellitus. Oxidative stress and dyslipidemia plays
an important role in the pathogenesis and complications
of diabetes. Policosanol is a mixture of primary aliphatic
alcohols purified from sugar cane wax. The objective of this
randomised, double-blinded and placebo-controlled pilot
study was to investigate the effect of policosanol treatment
on lipid profile and plasma oxidative variables in diabetic
patients with hypercholesterolemia.
Methods:
Thirty diabetic patients of both sexes, aged 50 to
70 years were enrolled in the study. Fifteen patients were
treated with policosanol (10 mg/day) and 15 with placebo
for 12 weeks. The primary efficacy variable was to significant
reduced low-density lipoprotein-cholesterol (LDL-C) values.
Plasma oxidative markers were secondary variables.
Results:
Baseline characteristics were well matched in both
groups. After 12 weeks policosanol produced significant
reductions of LDL-C and total cholesterol and increase in
high-density lipoprotein-cholesterol. In addition, serum
malondialdehyde significantly decreased and the total
antioxidant capacity of the plasma increased. There were
no significant changes in any of the variables in the placebo
group. Treatments were safe and well tolerated. No patient
withdrew from the study.
Conclusions:
Policosanol treatment favorably modified lipid
profile and plasma oxidative variables in diabetic patients.
Further studies should expand more data on the effects of
policosanol treatment in diabetic patients.
Speaker Biography
Julio C Fernández is a Senior Investigator in Clinical Trials Unit, National Centre for
Scientific Research, Havana city, Cuba. He has completed his BSc in Pharmaceutical
Sciences from Havana University Cube in 1996. He was awarded with PhD in
Pharmaceutical Sciences in 2003. He has published more than 130 publications and
presented more than 100 papers in various scientific events. His research interest
mainly focuses on clinical trials phase I-IV of different natural products: Policosanol,
Abexol, Prevenox, Palmex.
e:
julio.fernandez@cnic.edu.cu